Gefitinib ('Iressa', ZD1839) given in the 'Iressa' Expanded Access Programme in patients with non-small-cell lung cancer

被引：0
|
作者：
Chioni, A
Barbieri, F
Baldini, E
Orlandini, C
Ricci, S
Conte, PF
机构：
[1] Ciari Univ Hosp, Pisa, Italy
[2] Policlin Univ Hosp, Pisa, Italy
来源：
BRITISH JOURNAL OF CANCER | 2003年 / 89卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S26 / S27
页数：2
相关论文
共 50 条
  • [31] Gefitinib ('Iressa', ZD1839) in elderly patients with progressive pretreated non-small-cell lung cancer: results from the Istituto Clinico Humanitas
    Parra, HS
    Cavina, R
    Zucali, P
    Campagnoli, E
    Latteri, F
    Biancofiore, G
    Abbadessa, G
    Morenghi, E
    Santoro, A
    BRITISH JOURNAL OF CANCER, 2003, 89 : S33 - S33
  • [32] New hope for patients with non-small-cell lung cancer: gefitinib ('Iressa', ZD 1839) and other innovative therapies
    Goss, G
    EJC SUPPLEMENTS, 2003, 1 (08): : 1 - 1
  • [33] Prolonged survival and clinical benefits with gefitinib ('Iressa', ZD1839) in a patient with brain metastasis from non-small-cell lung cancer
    de la Cruz, J
    Giacomi, N
    BRITISH JOURNAL OF CANCER, 2003, 89 : S27 - S28
  • [34] Activity of a specific inhibitor, gefitinib (Iressa™, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancer
    Santoro, A
    Cavina, R
    Latteri, F
    Zucali, PA
    Ginanni, V
    Campagnoli, E
    Ferrari, B
    Morenghi, E
    Pedicini, V
    Roncalli, A
    Alloisio, M
    Ravasi, G
    Parral, HJS
    ANNALS OF ONCOLOGY, 2004, 15 (01) : 33 - 37
  • [35] Quality-of-life benefits for a patient with non-small-cell lung cancer and brain metastases taking gefitinib ('Iressa', ZD1839)
    van Zandwijk, N
    BRITISH JOURNAL OF CANCER, 2003, 89 : S34 - S34
  • [36] Experience from a large multi-centre expanded access programme (EAP) with gefitinib ('Iressa', ZD1839) as monotherapy in advanced non-small cell lung cancer (NSCLC)
    van Puijenbroek, R
    Bosquée, L
    Tits, G
    Germonpre, P
    Strobbe, E
    Vansteenkiste, J
    LUNG CANCER, 2005, 49 : S273 - S273
  • [37] ZD1839 (Iressa™):: For more than just non-small cell lung cancer
    Ranson, M
    ONCOLOGIST, 2002, 7 : 16 - 24
  • [38] Cell growth after withdrawal of gefitinib ('Iressa', ZD1839) in human lung cancer cells
    Satoh, H
    Ishikawa, H
    Nakayama, M
    Fujiwara, M
    Ohtsuka, M
    Sekizawa, K
    ONCOLOGY REPORTS, 2004, 12 (03) : 615 - 619
  • [39] Lessons from the 'Iressa' Expanded Access Programme: gefitinib in special non-small-cell lung cancer patient populations
    Stahel, R
    Rossi, A
    Petruzelka, L
    Kosimidis, P
    de Braud, F
    Bernardo, MM
    Souquet, PJ
    Parra, HS
    Gridelli, C
    BRITISH JOURNAL OF CANCER, 2003, 89 (Suppl 2) : S19 - S23
  • [40] A case of diffuse interstitial pneumonitis in a patient with stage IV non-small-cell lung cancer receiving gefitinib ('Iressa', ZD1839) treatment
    Gervais, R
    Chasles, J
    Rivière, A
    Michels, JJ
    BRITISH JOURNAL OF CANCER, 2003, 89 : S28 - S29
12345